ArticleThe New phytologist2022
A phytobacterial TIR domain effector manipulates NAD
Article in The New phytologist, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 72 citations in OpenAlex.
- A fungal subtilase-like protease SBT1 blocks rice immunity by erasing the MAPKKKα signaling node.Science advances · 2026Article
- Raw defines a TIR-fold cADPR hydrolase cooperating with dSarm in development and axon degeneration.Cell communication and signaling : CCS · 2026Article
- Article
- Molecular mechanisms of plant NLR activation and signalling.The Plant journal : for cell and molecular biology · 2026Review
- Precision Editing of NLRS Improves Effector Recognition for Enhanced Disease Resistance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- From gene-for-gene to NLRome-for-effectorome: decoding the dynamic interplay between phytopathogenic effector networks and plant immune systems.FEMS microbiology reviews · 2026Review
- TIR innovations in plant immunity.The New phytologist · 2026Review
- Adaptation without Dominance in Pseudomonas syringae Pathovars.Microbial ecology · 2025Article
- Cyclic-di-GMP controls Type III effector export and symptom development in Pseudomonas syringae infections via the export ATPase HrcN.PLoS pathogens · 2025Article
- Mapping the transcriptional landscape of algal resistance to viral infection reveals a core expression program.The New phytologist · 2025Article
- TheProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Multiple effectors trigger non-host resistance in Solanum americanum against Pseudomonas syringae.The Plant journal : for cell and molecular biology · 2025Article
- Evolutionarily ancient functions of enzymatic TIR proteins in innate immunity.Trends in immunology · 2025Review
- Purine-based infochemicals and immunometabolites: a comparative review of emerging signaling pathways in plants and animals.FEMS microbiology reviews · 2025Review
- Review
- A comprehensive review of soybean RNL and TIR domain proteins.Plant molecular biology · 2024Review
- Exploiting bacterial effector proteins to uncover evolutionarily conserved antiviral host machinery.PLoS pathogens · 2024Article
- Toll/interleukin-1 receptor (TIR) domain-containing proteins have NAD-RNA decapping activity.Nature communications · 2024Article
- Article
- Exploiting Bacterial Effector Proteins to Uncover Evolutionarily Conserved Antiviral Host Machinery.bioRxiv : the preprint server for biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Pseudomonas syringae DC3000 type III effector HopAM1 suppresses plant immunity and contains a Toll/interleukin-1 receptor (TIR) domain homologous to immunity-related TIR domains of plant nucleotide-binding leucine-rich repeat receptors that hydrolyze nicotinamide adenine dinucleotide (NAD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.